Since the early 2000s and the advent of the first guidance relating to mutagenic impurities developed by the European Medicines Agency (EMA), it has been necessary to assess the risk posed by mutagenic impurities. Although… Read more >
When a crisis occurs, hindsight is a great teacher. Any company developing or manufacturing products that impact human health can learn from the recent nitrosamine impurity contamination of angiotensin II receptor blockers (ARBs) by reviewing… Read more >
At Chiesi Group’s Chippenham laboratory in the UK, Waters’ UPLC systems with mass detection and informatics keep the team at the forefront of inhalation drug delivery products.
Learn how the ACQUITY QDa Mass Detector brings the power of mass detection for purification to Medicilon, helping this CRO meet the growing demand for outsourced services in the pharmaceutical and biotechnology industries.
Q&A from webinar on using targeted 2D LC (RP-RP) for effective impurity analysis to address peak coelutions The Waters pharmacuetical team recently hosted a webinar discussion how two-dimentional LC can offer a solution to analyze… Read more >
With access to multiple mass spectrometry systems of varying degrees of sophistication, Davy Guillarme (University of Geneva, Switzerland) wasn’t actively looking for new mass detection solutions. Nevertheless, the Waters ACQUITY QDa mass detector caught his eye.
Participating in the 16th annual International Conference on the Science of Botanicals (ICSB), it became clear that academic research institutions, regulatory agencies, and dietary supplement/herbal medicine manufacturers want the same thing – to keep consumers… Read more >